COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
The Food and Drug Administration authorized the emergency use of the Ascom telecare IP Nurse Call System and Eko electrocardiogram Low Ejection Fraction Tool.
The Centers for Medicare & Medicaid Services May 12 and May 14 will host calls for hospitals, health systems and providers on COVID-19.
Deaths were 75% higher than usual in New York City between March 11 and May 2, with most of the estimated 24,172 increase likely due to COVID-19, according to a report by the New York City Department of Health and Mental Hygiene released by the CDC.
The FDA authorized the emergency use of Fresenius Propoven 2% Emulsion, which the agency says "may be effective to maintain sedation via continuous infusion in patients greater than 16 years old with suspected or confirmed COVID-19 who require mechanical ventilation in an ICU setting."
The Centers for Medicare & Medicaid Services recently provided hospitals with new Medicare blanket waivers to address the COVID-19 public health emergency.
The federal government continues to learn lessons about distributing COVID-19 therapeutics, such as remdesivir, Food and Drug Administration Commissioner Stephen Hahn, M.D., said at a Senate Health, Education, Labor and Pensions Committee hearing.
The Centers for Disease Control and Prevention launched the COVID-19 Data Tracker, a website showing data on U.S. laboratory testing and cases reported to CDC from state health departments and territorial jurisdictions.
The Food and Drug Administration expanded the list of drugs covered under newly flexible compounding policies to include two that may be in short supply because of the COVID-19 pandemic: morphine sulfate and epinephrine.
The Food and Drug Administration issued the first emergency use authorization for a COVID-19 antigen test, which can quickly detect the SARS-CoV-2 virus in a nasal swab sample.
FDA revised its April 3 emergency use authorization for N95 and similar respirators made in China to remove certain respirators that failed to demonstrate at least 95% particulate filtration efficiency when tested by the National Institute for Occupational Safety and Health.